There were no differences in survival after treatment with oxaliplatin (Fig. 4B); however, compared with patients with non–CCNE1-amplified gastric adenocarcinoma, patients with CCNE1-amplified gastric adenocarcinoma showed a trend toward shorter survival after receiving trastuzumab (HR = 1.694, 95% CI: 0.873–3.289, P = 0.115; Fig. 4C). Here, CCNE1 is linked to gastric adenocarcinoma.